文献速递耳科与耳神经

低剂量阿司匹林与中枢性老年性聋:ASPREE随机临床试验子研究

Low-Dose Aspirin and Central Presbycusis: A Substudy of the ASPREE Randomized Clinical Trial.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2026-01-01

该研究为ASPREE随机对照试验的子研究,纳入124名70岁以上健康老年人,随机接受每日100mg肠溶阿司匹林或安慰剂,随访5年。结果显示低剂量阿司匹林对中枢性老年性聋无临床重要影响,但听觉神经功能在5年内显著退化。

要点

  • 低剂量阿司匹林未减缓中枢听觉通路退化或改善言语感知。
  • 健康老年人5年内皮质反应潜伏期延长、振幅下降,双耳言语感知退化。
  • 需进一步研究其他干预措施以延缓年龄相关听觉功能下降。

核心结论

  • 低剂量阿司匹林对中枢性老年性聋无临床重要影响。
  • 健康老年人5年内出现显著的听觉神经和功能听力退化。

研究设计与样本

  • 嵌入ASPREE随机安慰剂对照试验的子研究,在澳大利亚墨尔本Monash生物医学影像中心2014至2019年进行。
  • 纳入124名70岁及以上健康老年人,随机接受每日100mg肠溶阿司匹林或匹配安慰剂。
  • 参与药物试验至少2.5年,随后进行1年和2年试验后评估,听觉评估在基线及18、36、48、60个月进行。
  • 数据分析时间为2025至2026年。

主要发现

  • 皮质反应潜伏期随研究时间增加(N1:每年1.3毫秒;P2:每年0.9毫秒),但无阿司匹林效应。
  • N1/P2振幅随时间下降(每年0.2 uV),阿司匹林有主效应但无阿司匹林与时间点交互作用,提示组间差异源于基线并维持。
  • 双耳言语感知在目标与噪声空间分离条件下恶化,接收阈值每年降低0.1 dB;语音与噪声同位置时无变化。
  • 任何条件下均无阿司匹林效应。

临床怎么用

  • 不应将低剂量阿司匹林用于延缓老年性聋的临床目的。
  • 对健康老年人应关注5年内可检测到的听觉神经功能退化,适时评估听力。

局限性

  • 样本量较小(124人),可能限制统计效能。
  • 研究人群为健康老年人,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Age-related hearing loss (presbycusis) affects more than 50% of individuals 70 years or older and is associated with communication difficulty, social isolation, and cognitive decline. Microvascular and inflammatory conditions are known to affect peripheral and central auditory processes; as such, aspirin may have an important role in slowing age-related dysfunction. OBJECTIVE: To investigate whether low-dose aspirin affects the rate of central auditory pathway degeneration in older adults. DESIGN, SETTING, AND PARTICIPANTS: This study was embedded within the parent Aspirin in Reducing Events in the Elderly (ASPREE) Project, which was a randomized, placebo-controlled trial that explored aspirin effects on healthy aging. Enrollment occurred after randomization. It was conducted at Monash Biomedical Imaging Center (Melbourne, Victoria, Australia) from 2014 to 2019. Eligible adults aged 70 years or older at baseline received either 100 mg daily of enteric-coated aspirin or a matching placebo. Individuals participated in the drug trial for at least 2.5 years and then underwent 1-year and 2-year posttrial reviews. Auditory assessment was carried out at baseline and 18, 36, 48, and 60 months. Data were analyzed from 2025 to 2026. MAIN OUTCOMES AND MEASURES: Type and severity of auditory dysfunction were evaluated via electrophysiologic (cortical auditory evoked potentials) and perceptual (speech-in-noise) assessment. Group outcomes were compared using mixed-linear regression models that adjusted for participants' age and hearing level. RESULTS: Of 124 individuals (mean [SD] age, 72.8 [3.5] years; 60 female individuals [48.4%]), 61 (49.2%) received aspirin and 63 (50.8%) received placebo. Cortical response latencies increased over the course of study (N1: 1.3 milliseconds per year; P2: 0.9 milliseconds per year), but there was no aspirin effect. Similarly, N1/P2 amplitudes decreased over time (0.2 uV per year). In this case, there was a main effect for aspirin, but there was no aspirin/time point interaction, suggesting that the result was due to a group difference at baseline that was maintained throughout the study. Binaural speech perception deteriorated for listening conditions for which target and noise sources were spatially separated, with reception thresholds decreasing by 0.1 dB per year. When speech and noise were colocated, there was no change. There was no aspirin effect for any condition. CONCLUSIONS AND RELEVANCE: This substudy of randomized clinical trial showed that there was no clinically important effect of low-dose aspirin on central presbycusis. However, more investigation (of aspirin and other treatment options) is warranted, as the longitudinal findings revealed substantial auditory neural and functional hearing deterioration over a relatively short (5-year) period in healthy older adults. TRIAL REGISTRATION: anzctr.org.au Identifier: ACTRN12614000496617.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Rance G, Zanin J, Britt CJ, et al. Low-Dose Aspirin and Central Presbycusis: A Substudy of the ASPREE Randomized Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2026. PMID: 41954898. doi:10.1001/jamaoto.2026.0338

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。